Kalaris Therapeutics, Inc.
KLRSFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Kalaris Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Kalaris Therapeutics, Inc. — 10-K filed Feb 12, 2021
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 4, 2026. The latest institutional report shown is dated Jun 30, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 2024-12-31 | 408,688 | $3.95M | SEC filing |
- Each value is checked against Kalaris Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- 19 rows left out: the value per share they report is far from Kalaris Therapeutics, Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so they may describe another security or share class.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security. Filers with a row left out above, or with no row above to check, are not listed.
- EcoR1 Capital, LLC: 11,294,585 shares reported 2024-09-30; 408,688 shares reported 2024-12-31.
35 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS · Director, 10% owner | Common Stock | P — Open market or private purchase | +244,300 | 4.83 | SEC filing |
| 2026-03-20 | Hagen Brett R · Chief Accounting Officer | Common Stock | S — Open market or private sale | −1,915 | 6.72 | SEC filing |
| 2025-12-18 | AKKARAJU SRINIVAS · Director, 10% owner | Common Stock | P — Open market or private purchase | +479,847 | 10.42 | SEC filing |
| 2025-03-26 | Hagen Brett R · Chief Accounting Officer | Common Stock | S — Open market or private sale | −907 | 8.97 | SEC filing |
| 2025-02-21 | Miller Edward · General Counsel | Common Stock | S — Open market or private sale | −106 | 10.08 | SEC filing |
| 2025-02-21 | Sinha Vikas · See Remarks | Common Stock | S — Open market or private sale | −303 | 10.08 | SEC filing |
| 2025-02-21 | Hagen Brett R · Chief Accounting Officer | Common Stock | S — Open market or private sale | −96 | 10.08 | SEC filing |
| 2025-01-23 | Miller Edward · General Counsel | Common Stock | S — Open market or private sale | −47 | 9.45 | SEC filing |
Showing 8 of 13 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-03 | Dybbs Michael · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | Jovan-Embiricos Morana · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | ADAMIS ANTHONY P · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | Ferrara Napoleone · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | Hallal David · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | AKKARAJU SRINIVAS · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-06-03 | PATTERSON LEONE D · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,000 | SEC filing |
| 2026-03-19 | Gall Matthew · Chief Financial Officer | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +95,000 | SEC filing |
Showing 8 of 14 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-20 | AKKARAJU SRINIVAS · Director, 10% owner | Common Stock | J — Other acquisition or disposition | −66,906 | SEC filing |
| 2026-05-20 | AKKARAJU SRINIVAS · Director, 10% owner | Common Stock | J — Other acquisition or disposition | +4,471 | SEC filing |
| 2026-05-20 | AKKARAJU SRINIVAS · Director, 10% owner | Common Stock | J — Other acquisition or disposition | +14,937 | SEC filing |
Showing 3 of 3 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.